Rhabdomyolysis in a 48-Year-Old Man With Hepatitis B-Induced Cirrhosis

[Guest guest]

http://journals.lww.com/amjmedsci/Abstract/2011/07000/Rhabdomyolysis_in_a_48_Yea\

r_Old_Man_With_Hepatitis.17.aspx

American Journal of the Medical Sciences:

July 2011 - Volume 342 - Issue 1 - pp 73-75

doi: 10.1097/MAJ.0b013e31821a520e

Case Report

Rhabdomyolysis in a 48-Year-Old Man With Hepatitis B-Induced Cirrhosis

Dang, Shuangsuo MD, PhD; Gao, Ning PhD; Zhang, Xin PhD; Jia, Xiaoli PhD

Abstract

Telbivudine (beta-l-2′-deoxythymidine) is an orally administered nucleoside

analog drug approved for the treatment of patients with chronic hepatitis B

since 2006. Initially, it was regarded as being generally well tolerated, with

low adverse reaction profiles and no dose-limiting toxicity. Recently, with the

result of the telbivudine worldwide phase III GLOBE trial and other clinical

experiments, cases of myopathy and neuropathy have been reported undergoing

long-term telbivudine treatments. Telbivudine-induced myopathy has been

characterized by muscle pain, weakness and moderately elevated creatine kinase

levels during treatments, although no severe adverse events have been observed.

Rhabdomyolysis has not reported in any patient.

© Copyright 2011 Southern Society for Clinical Investigation